

Database creation on the feasibility of galenic modification of oral anticancer drugs

C. Gazel¹, C. Fresneau¹, P. Claraz¹, F. Puisset¹, C. Guillemot¹ - ¹Pharmacie à Usage Intérieur (PUI), IUCT-Oncopole

COM24-44072

Introduction



Patients suffering from
swallowing disorders (SD)

Galenic adaptation (oral liquid form) = preserve the therapeutic line



Oral anticancer drugs (OADs) :

- increasingly being commercialized
- considered *a priori* carcinogenic, mutagenic and/or reprotoxic (CMR) → galenic modification possible if equipment to protect the environment.

Objective : take stock
of galenic alternatives
available of OADs for
patients with SD →
provide standardised,
safe and quick answer.

Materials & methods

- Each drug commercialized available at IUCT-Oncopole
- **Research** :

Availability of marketed adapted galenic (oral liquid form)

Yes

Switch

No

Industrial and literature data :

CMR, possibility of galenic modification,
compatibility with nasogastric tube (NGT),
bioéquivalence

Feasibility test

Dissolution condition

NGT obstruction test

TDM

therapeutic drug
monitoring

Results

70 AO
identified


100%
CMR

70%
TDM available

0%
Obstruction

Note : Adsorption on NGT → no data

Suitable galenic available for patient with SD



- Marketed
- Deconditioning by hospital pharmacy
- Extemporaneously modified in the ward
- Magistral preparation
- No galenic alternative

Conclusion

- **Oral liquid form** proposed to hospitalized patient (if no marketed form) : **70% of OADs** available at IUCT-Oncopole
- **Little data** to assess the impact of galenic modification on **pharmacokinetics** → **TDM** strongly recommended : possible for **70% of OADs**
- **Interests** :
 - **Immediate response** to the clinician
 - Give the patient **access to therapeutic** despite his SD
 - Ensure **no exposition** for **nurses** to toxic agents

Note : discuss the feasibility of the alternative at the patient's home